Can only speak for myself, but given the SP, maybe my view is...

Can only speak for myself, but given the SP, maybe my view is not unique ...

I called Her-Vaxx a duster quite early in the piece. Although I had divested a significant portion of my holding at that time, I attended the Yuman and Saul road shows and after hearing them speak, decided to keep the rest of my investment.

From my perspective, they were the only remaining credible people associated with IMU.

Axel had been booted.

Leslie makes me cringe when I hear her speak, and I don't understand how she gets away with the "nudge-nudge, wink-wink" comments, year after year with nothing coming to fruition.

Paul. Nuff said.

Monil ...

The rest of the board just perform as Hopper stooges.

So, given the painfully slow - arguably backward - progress toward commercialising anything, the involvement and enthusiasm of Yuman and Saul, were, IMO, the only things going for IMU in the past 18 months.

The other influence is that whenever IMU has gone quite, its always surprised to the downside when it finally announces something - if it announces anything at all. Those three combination HER-Vaxx trials are a case in point.

As much as people would like to believe that Yuman and Saul think Paul and Leslie are the best things since sliced bread, the reality is that their attraction to IMU is simply financial. Its a vehicle for them to progress / test their research, they couldn't care less about who's in charge. So them slinking into the background doesn't bode well IMO.

Perhaps you understand the science better than the vast majority of investors so these things don't concern you. I'm giving the perspective of one who doesn't and so bases investment on (a) the team involved and (b) progress toward commercialisation as I understand it.

Questions for you: Given your obvious scientific understanding and the amount of research you do - did you reach the conclusion that HER-Vaxx was in trouble before IMU confirmed its deprioritisation? Were you concerned that IMU had apparently taken the decision to deprioritise HER-Vaxx (all those non-started or "active, not-recruiting" combination trials) some time before confirming as much? Do you trust that the same isn't happening with CF33 / Oncarlytics? Do you put the SP decline and the fact that IMU has had to do capital raises at ever lowering prices down to market stupidity, or do you think that the personalities and their relative prominence might be contributing?